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Topical administration is the most common and acceptable use
for the treatment of ocular disease. However, the major problem
of ocular drug delivery is the rapid drug elimination from the
pre-ocular area leading to poor ocular bioavailability [1].
Nanostructure lipid carriers (NLC) possess a significant en-
hancement in ocular bioavailability by increasing the
permeability and mucoadhesive property [2]. In this study, in-
domethacin (IND), non-steroidal anti-inflammatory, was used
as a model drug [3]. Thus, IND loaded NLC (IND-NLC) were de-
veloped and characterized. In addition, the mucoadhesive
property of IND-NLC was investigated.
IND-NLC were prepared by high pressure homogenization
(HPH) technique with various types of solid lipid and surfac-
tant.The mean particle size, Zeta potential and polydispersity
index were observed.The entrapment efficacy of IND-NLC was
determined by HPLC method. Ex vivo mucoadhesive test was
investigated using porcine eye cornea.The particle size of IND-
NLC was in a range of 40–250 nm with a narrow distribution.
The surface of particle exhibited negatively charge of 20–
30 mV. The high entrapment efficacy within the range of 60–
70% was observed. In addition, IND-NLC exhibited a 2-fold
mucoadhesive property than IND solution. This study indi-
cated that the mucoadhesiveness of IND-NLC was successfully
prepared by HPH technique.The encapsulation procedure was
successfully developed with entrapment efficacy higher than
60%.Therefore, NLC could reasonably be considered as a prom-
ising for ocular drug delivery system.
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Fig. 1 – Schematic drawing of the apparatus for ex vivo mucoadhesive tests (A) and ex vivo mucoadhesive of IND-NLC on
porcine cornea (B).
175a s i an j o u rna l o f p h a rma c eu t i c a l s c i e n c e s 1 1 ( 2 0 1 6 ) 1 7 4 – 1 7 5
